Nyxoah (NYXH BR) stock market data APIs
€1.3212
0.01(0.8%)
as of September 18, 2026
Try our APIs with
free plan!
Nyxoah Financial Data Overview
Price chart is built with
Anychart
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Prev. Close
1.3212
Open
1.3282
High
1.367
Low
1.3074
52 wk Range
1.14-6.36
Market Cap
133 M
Shares Outstanding
102 M
Revenue
21 663 K
EPS
-0.58
Beta
0.963
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nyxoah data using free add-ons & libraries
Get Nyxoah Fundamental Data
Nyxoah Fundamental data includes:
- Net Revenue: 21 663 K
- EBITDA: -82 744 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nyxoah News
New
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Key Points Interested in Nyxoah SA? Here are five stocks we like better. Nyxoah said its U.S. Genio launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients i...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are...
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Nyxoah SA (NYXH) reports results for the quarter ended September 2025. While this widely-known consensus outlook is imp...
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Nyxoah NYXH has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first comme...
Get Nyxoah fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
